基本情報
- CAS
22059-60-5- 標準SMILES
CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C.O=P(O)(O)O- InChIKey
CGDDQFMPGMYYQP-UHFFFAOYSA-N- 分子式
- C21H32N3O5P
- 平均分子量
- 437.5 g/mol
- 単同位体質量
- 437.20795813
概要
Disopyramide phosphate is an organoammonium phosphate. It is functionally related to a disopyramide.
名称と識別子
- 優先名称
- Disopyramide Phosphate
- IUPAC
- 4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide;phosphoric acid
- 現地名
- ジソピラミドリン酸塩
- 英語名
- Disopyramid phosphate
- 分子式
- C21H32N3O5P
- 分子量
- 437.47
名称と別名
DISOPYRAMIDE PHOSPHATE22059-60-5NorpaceRythmodanNorpace CrDirythmin saDiso-durilesSC-7031 PHOSPHATENSC-756744N6BOM1935WSC-13957CHEBI:4658
名称をさらに表示
α-[2-[ビス(1-メチルエチル)アミノ]エチル]-α-フェニル-2-ピリジンアセトアミド·りん酸塩ジソピラミドホスファートノルパースりん酸ジソピラミドリスモダンリトモダンジソピラミドりん酸塩りん酸ジソピラアミドジソピラミド リン酸塩ジソピラミドリン酸塩 (JAN)α-[2-[ビス(1-メチルエチル)アミノ]エチル]-α-フェニル-2-ピリジンアセトアミド・りん酸塩sc13957disopyramid phosphateDisopyramide phosphate CRSDISOPYRAMIDE PHOSPHATE SALTDisopyramid phosphate USP/EP/BPDisopyramide Phosphate (200 mg)
DTXSID309446852-(1-(Ammoniocarbonyl)-3-(diisopropylammonio)-1-phenylpropyl)pyridinium phosphate4-(diisopropylamino)-2-phenyl-2-(2-pyridyl)butanamide;phosphoric acidDirythminRythmodan retDirythmin-saIsomide crRefChem:56639
データベース識別子
物性
構造計算による物性
- 極性表面積
- 137 Ų
- 水素結合供与体数
- 4
- 水素結合受容体数
- 7
- 回転可能結合数
- 8
- 重原子数
- 30
- 形式電荷
- 0
- 複雑度
- 459
実験および物理化学的性質
Solubility>65.6 [ug/mL] (The mean of the results at pH 7.4)
Human Drugs
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Collision Cross Section179.9 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
物理化学的性質
- 融点
- 202 · 202-204°C
- 貯蔵温度
- 2 · 2-8°C
- 溶解性
- DMSO（微量、加熱、超音波処理）、メタノール（微量）、水（微量）
- 外見
- solid
- 色
- ホワイトからオフホワイト
- 主な用途
- 医薬品（低分子化合物）
- InChI
- 1S/C21H29N3O.H3O4P/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19;1-5(2,3)4/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25);(H3,1,2,3,4)
- InChIKey
- CGDDQFMPGMYYQP-UHFFFAOYSA-N
- SMILES
- C(CCN(C(C)C)C(C)C)(C1=NC=CC=C1)(C1=CC=CC=C1)C(=O)N.P(=O)(O)(O)O
安全と法規制
安全情報は参考情報です。供給元の安全データシート（SDS）、適用法令、専門家による評価に代わるものではありません。
GHS分類
GHS Classification
Warning
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 41 reports by companies from 2 notifications to the ECHA C&L Inventory.
危険有害性情報
Regulatory InformationDisopyramide phosphate: Does not have an individual approval but may be used under an appropriate group standard
Other Safety InformationIMAP assessments - 2-Pyridineacetamide, .alpha.-[2-[bis(1-methylethyl)amino]ethyl]-.alpha.-phenyl-, phosphate (1:1): Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (100%)
毒性情報
Drug Induced Liver Injury
Drug Induced Liver Injury Rank (DILIrank 2.0)
Disopyramide phosphate
vLess-DILI-concern
2
Adverse reactions
DOI:10.1016/j.drudis.2016.02.015
安全データ
- wgk
- 3
- rtecs
- UR8440000
- hs_code
- 2933399090
- risk_code
- 22
- hazard_code
- Xn
- safety_code
- 36
- Hazard Classifications
- Acute Tox. 4 Oral
化学と産業
薬理情報
FDA Pharmacological Classification
DISOPYRAMIDE PHOSPHATE
Antiarrhythmic [EPC]
MeSH Pharmacological Classification
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.
A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS.
応用分野
使用Cardiac depressant (anti-arrhythmic).
一般的な説明Disopyramide phosphate, -[2(diisopropylamino)ethyl]- -phenyl-2-pyridineacetamidephosphate (Norpace), is an oral and intravenousclass IA antiarrhythmic agent. It is quite similar to quinidineand procainamide in its electrophysiological properties, inthat it decreases phase 4 diastolic depolarization, decreasesconduction velocity, and has vagolytic properties.31 It is usedclinically in the treatment of refractory, life-threatening ventriculartachyarrhythmias. Oral administration of the drugproduces peak plasma levels within 2 hours. The drug isbound approximately 50% to plasma protein and has a halflifeof 6.7 hours in humans. More than 50% is excretedunchanged in the urine. Therefore, patients with renal insufficiencyshould be monitored carefully for evidence ofoverdose. Disopyramide phosphate commonly exhibits sideeffects of dry mouth, constipation, urinary retention, andother cholinergic blocking actions because of its structuralsimilarity to anticholinergic drugs.
上流・下流製品情報
上流原料
関連反応
0 件
現在のフィルター条件では反応記録がありません。
化合物ノート
読み込み中…